Choriocarcinoma of Extremely High Risk with Hypercalcemia: A Case Report and Literature Review

doi:10.12280/gjfckx.20210655

Abstract

Abstract:

Choriocarcinoma is a kind of gynecological tumor with extremely high mortality. With the rational application of chemotherapeutic drugs, choriocarcinoma can also get a satisfactory curative effect. Hypercalcemia is often associated with malignant tumors, but the incidence of hypercalcemia in choriocarcinoma is very low. We report a case of diagnosis and treatment of extremely high-risk choriocarcinoma (Ⅱ, 13) characterized by β-hCG up to 1 400 588.00 IU/L and hypercalcemia in blood. During the process of diagnosis and treatment, the patients were treated successfully by a combination of treatment about calcium reduction, chemotherapy and surgery. After β-hCG decreased to the normal range, the patient refused to receive consolidation chemotherapy. After 6 months of close follow-up, we don′t observe the disease bounces back. This case provides a new thinking for the clinical manifestation, diagnosis, treatment and follow-up of choriocarcinoma.

Key words: Choriocarcinoma, Choriocarcinoma,non-gestational, Chorionic gonadotropin,beta subunit,human, Hypercalcemia, Antineoplastic combined chemotherapy protocols

CHENG Zhe, LIU Yu-zhen, ZHANG Hai-feng. Choriocarcinoma of Extremely High Risk with Hypercalcemia: A Case Report and Literature Review[J]. Journal of International Obstetrics and Gynecology, 2022, 49(2): 238-240.

Figures/Tables 2

References 9

[1]	赵琳, 李晓牧. 恶性实体瘤难治性高钙血症与骨化三醇升高相关[J]. 中华内分泌代谢杂志, 2021, 37(7):662-667. doi: 10.3760/cma.j.cn311282-20201230-00870. doi: 10.3760/cma.j.cn311282-20201230-00870
[2]	常彦升. 恶性肿瘤与PHPT所致高钙血症临床特点研究[D]. 兰州:兰州大学, 2019.
[3]	王丽娟, 林海雪, 冯凤芝, 等. 《EOTTD妊娠滋养细胞疾病诊治临床实践指南》解读[J]. 中国实用妇科与产科杂志, 2020, 36(8):729-735. doi: 10.19538/j.fk2020080114. doi: 10.19538/j.fk2020080114
[4]	蒋芳, 向阳. 妊娠滋养细胞肿瘤药物治疗的现状及进展[J]. 肿瘤预防与治疗, 2019, 32(2):175-179. doi: 10.3969/j.issn.1674-0904.2019.02.013. doi: 10.3969/j.issn.1674-0904.2019.02.013
[5]	Bolze PA, Riedl C, Massardier J, et al. Mortality rate of gestational trophoblastic neoplasia with a FIGO score of ≥13[J]. Am J Obstet Gynecol, 2016, 214(3):390.e1-e8. doi: 10.1016/j.ajog.2015.09.083. doi: 10.1016/j.ajog.2015.09.083
[6]	刘迎见, 刘国良. 妊娠甲亢综合征[J]. 实用糖尿病杂志, 2019, 15(3):4-5.
[7]	Filipović B, Šošić-Jurjević B, Ajdžanović V, et al. The phytoestrogen genistein prevents trabecular bone loss and affects thyroid follicular cells in a male rat model of osteoporosis[J]. J Anat, 2018, 233(2):204-212. doi: 10.1111/joa.12828. doi: 10.1111/joa.12828 pmid: 29761487
[8]	卢慧. Graves病甲亢并发高钙血症的危险因素分析[D]. 青岛:青岛大学, 2019.
[9]	赵峻, 向阳. 妊娠滋养细胞肿瘤治疗中的过度与不足[J]. 中国实用妇科与产科杂志, 2011, 27(7):497-500.

[1]	ZHU Dan-mo, LIU Qin. A Case of Choriocarcinoma Discovered after Preterm Cesarean Section [J]. Journal of International Obstetrics and Gynecology, 2024, 51(5): 546-548.
[2]	ZOU Qiao-jian, YAO Shu-zhong, CHEN Yi-li, LIU Jun-xi. Research Progress in Copper and Ovarian Cancer [J]. Journal of International Obstetrics and Gynecology, 2024, 51(2): 215-219.
[3]	SHEN Yan-qing, CHEN Ye, SHI Yu-xiang, HUANG Zeng-fa, CAO Ying. A Case Report of Uterine High-Grade Neuroendocrine Carcinoma with Endometrioid Adenocarcinoma [J]. Journal of International Obstetrics and Gynecology, 2023, 50(6): 668-672.
[4]	GUAN Hong-fei, SHI Li-li, LI Su-rong, CHENG Hua. Misdiagnosis of Ovarian Non-Gestational Choriocarcinoma in Adolescents: A Case Report and Literature Review [J]. Journal of International Obstetrics and Gynecology, 2023, 50(3): 309-312.
[5]	PAN Zhong-mian, FENG Li-yuan, LI Li. New Progress in Treatment of Neuroendocrine Carcinoma of the Cervix [J]. Journal of International Obstetrics and Gynecology, 2023, 50(1): 35-38.
[6]	WU Si-yu, LIU Chuan-li, ZHANG Yan, SUN Yang, CHEN Jun, CHEN Xiao. Adolescent Mixed Ovarian Germ Cell Tumor: A Case Report and Literature Review [J]. Journal of International Obstetrics and Gynecology, 2022, 49(5): 552-555.
[7]	CHANG Xin, HAN Lu. Research Progress of Drugs for Maintenance Treatment for Platinum-Sensitive Recurrent Ovarian Cancer [J]. Journal of International Obstetrics and Gynecology, 2022, 49(4): 382-387.
[8]	GUO Yi-lin, WANG Wu-liang. Apatinib Mesylate Combined with Etoposide in the Treatment of Platinum Resistant Recurrent Ovarian Cancer: A Report of Two Cases [J]. Journal of International Obstetrics and Gynecology, 2022, 49(4): 411-414.
[9]	SHI Yi-fu, LI Juan-qing. Collection and Interpretation of Medical Terms of Gestational Trophoblastic Disease/Neoplasia [J]. Journal of International Obstetrics and Gynecology, 2021, 48(5): 569-574.
[10]	CHU Hui-hui, LIU Qian. Research Progress in Clinical Treatment of Ovarian Cancer [J]. Journal of International Obstetrics and Gynecology, 2021, 48(4): 443-447.
[11]	PAN Zhong-mian, SHI Feng-juan, LI Li. Clinical Features and Treatment Analysis of Small Cell Neuroendocrine Carcinoma of the Cervix [J]. Journal of International Obstetrics and Gynecology, 2021, 48(4): 467-471.
[12]	JU Yu-ye, ZHANG Fang-fang, WANG Xiao-hui. Current Status and Progress of Treatment of Recurrent Cervical Cancer [J]. Journal of International Obstetrics and Gynecology, 2021, 48(1): 56-60.
[13]	FENG Shu-jie, ZHOU Qi-min, HE Ling-ling, LI Rui-yan, YU Xiao-yun, WANG Hai-lin. Adjuvant Therapy of Uterine Sarcoma [J]. Journal of International Obstetrics and Gynecology, 2020, 47(5): 531-535.
[14]	NIU Xing-yan, ZHANG Dong-ping, LI Fei-xia, PENG Yun-hua. Advances in Chemotherapy for Ovarian Malignant Tumors [J]. Journal of International Obstetrics and Gynecology, 2020, 47(2): 125-128.
[15]	ZHANG Jia-jun, WANG Xiao-hui. Current Status and Progress in the Treatment of Uterine Serous Carcinoma [J]. Journal of International Obstetrics and Gynecology, 2019, 46(5): 560-563.